Skip to main content

Cost-Effectiveness Research


For the first-line treatment of FL, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab-abbs or rituximab-pvvr plus chemotherapy in the United States.
Conference Coverage
In comparison with a biomarker-based strategy, first-line niraparib-for-all maintenance therapy is cost-effective for…
Conference Coverage
Minimally invasive surgery is cost-effective compared with laparotomy for suspicious ovarian masses, even though it is…
KTE-X19 is a potentially cost-effective alternative to the current standard of care for relapsed/refractory MCL.
Ali Khaki, MD, discusses results from a cost-effectiveness analysis comparing neoadjuvant immune checkpoint inhibition…
Back to Top